rs2078371 — TSPAN2

Regulatory variant in the TSPAN2/NGF locus on chromosome 1p13

See your personal result for TSPAN2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TSPAN2/NGF Locus — One of the Strongest Migraine Risk Signals in the Genome

On chromosome 1p13, two genes sit in close proximity: TSPAN2 (tetraspanin-2, a membrane scaffold protein) and NGF (nerve growth factor, a neurotrophin critical for the development and sensitization of pain-sensing neurons).

The Mechanism

The C allele at rs2078371 sits in the intergenic region between TSPAN2 and NGF and is annotated as a downstream regulatory variant near LINC01765, a long non-coding RNA in this locus. The precise molecular mechanism remains under investigation, but the most compelling biological model points to NGF (nerve growth factor)11 NGF (nerve growth factor)
a secreted neurotrophin that binds TrkA receptors on small-diameter trigeminal sensory neurons, upregulating TRPV1, TRPA1, and Nav1.8 — the ion channels that amplify pain signals during migraine. When NGF is overexpressed or its signalling is dysregulated, trigeminal afferents become hyperexcitable — a state known as peripheral sensitization, in which normally sub-threshold stimuli (light, sound, head movement) trigger pain.

TSPAN2 is a tetraspanin scaffold protein expressed in oligodendrocytes and in endothelial cells. It organizes cell-surface signalling complexes and may influence the local vascular and neuronal environment of the meninges, the pain-sensitive membranes surrounding the brain. Whether the locus effect is mediated through NGF expression, through TSPAN2 function in meningeal cells, or through the LINC01765 non-coding RNA regulating one or both genes is not yet resolved. The GWAS signal pointing to rs2078371 as a tag variant does not identify the causal allele or the gene it acts on — it marks a chromosomal region where one or more regulatory variants alter migraine susceptibility through this cluster of interacting genes.

The Evidence

The genetic evidence is robust across large-scale GWAS:

Anttila et al. 201322 Anttila et al. 2013
Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nature Genetics. established the TSPAN2 region at chromosome 1p13 as one of five newly discovered migraine loci in 23,285 cases, providing the first genome-wide-significant evidence for this chromosomal region. Gormley et al. 201633 Gormley et al. 2016
Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics. confirmed the signal in a much larger meta-analysis, cementing the locus as one of the most reliably replicated in migraine genetics.

Practical Actions

Migraine management for C allele carriers is dominated by reducing triggers that amplify peripheral sensitization — the mechanism the locus implicates. Three interventions have specific relevance:

Anti-NGF pharmacology is the most mechanistically targeted approach. Anti-NGF monoclonal antibodies (tanezumab, fasinumab) have been studied extensively for pain conditions driven by peripheral sensitization and have been tested in migraine prevention contexts. While none are yet approved specifically for migraine, the biological logic is direct: if elevated NGF activity at this locus drives trigeminal hyperexcitability, dampening NGF signalling addresses the root mechanism. CGRP-pathway treatments (erenumab, fremanezumab, galcanezumab — all approved for migraine prevention) act downstream of the same trigeminal sensitization cascade.

Trigger mapping and early abortive treatment are behavioural interventions with strong evidence specifically for MO patients with a high peripheral sensitization component. Cutaneous allodynia (scalp tenderness during migraine) is a clinical marker of peripheral sensitization; carriers experiencing it should treat attacks early with triptans before central sensitization develops, since triptans lose efficacy once central sensitization is established.

Interactions

The rs6330 variant in the NGF coding region is a related SNP in the same gene. Carriers of both rs2078371-C (GWAS regulatory signal) and rs6330-T (NGF coding variant associated with migraine with aura) represent compound risk at the same biological locus, though these are independent associations. The combination has not been formally studied in joint analysis.

rs11172113 (near LRP1) and rs10166942 (near TRPM8) are other migraine GWAS loci with distinct mechanisms that may interact additively with TSPAN2/NGF locus risk. Compound actions across multiple migraine-risk loci should be considered when users carry multiple high-risk genotypes.

Genotype Interpretations

What each possible genotype means for this variant.

TT Low-Risk Genotype Normal

Common genotype at the TSPAN2/NGF locus — population-typical migraine susceptibility

You carry two copies of the T allele at rs2078371, which is the reference allele at this position. This is the most common genotype globally, found in approximately 74% of people. The T allele is not associated with elevated migraine risk at this locus; your TSPAN2/NGF regulatory region is not a genetic contributor to migraine susceptibility based on current evidence.

CT Heterozygous Risk Intermediate

One copy of the migraine risk allele — modestly elevated susceptibility, especially for migraine without aura

The TSPAN2/NGF locus sits at chromosome 1p13, between two biologically plausible migraine genes: TSPAN2 (a tetraspanin membrane scaffold) and NGF (nerve growth factor, which sensitizes trigeminal pain fibres). The regulatory variant rs2078371-C likely alters expression of one or both genes in pain-relevant tissues, increasing the likelihood of trigeminal sensitization during migraine episodes.

CC High-Risk Genotype High Risk

Two copies of the migraine risk allele — highest genetic susceptibility at this locus, with strong bias toward migraine without aura

Homozygosity for the C allele means both copies of the regulatory region near TSPAN2 and NGF carry the risk-associated variant.